SCHEMBL7227159

SCHEMBL7227159

COc1cccc(OC(F)(F)F)c1B(O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.46
ORAI1 Q96D31 1/20 0.44
ORAI2 Q96SN7 1/20 0.44
ORAI3 Q9BRQ5 1/20 0.44
KCNK3 O14649 1/20 0.43
KCNK9 Q9NPC2 1/20 0.43
ALDH1A1 P00352 2/20 0.38
TP53 P04637 2/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
CYP3A4 P08684 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
ALOX12 P18054 1/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL203282 0.84 ENPP2 (0.60) ENPP2ORAI1ORAI2ORAI3ALDH1A1
SCHEMBL29956642 0.82 KCNK3 (0.35) ENPP2ORAI1ORAI2ORAI3KCNK3
SCHEMBL29950745 0.80 ALDH1A1 (0.35) KCNK3KCNK9ALDH1A1TP53KDM4E
SCHEMBL30995614 0.80 EPHX2 (0.36) KCNK3KCNK9KDM4EGAA
SCHEMBL18190674 0.79 GRIA1 (0.40) KCNK3KCNK9KDM4EGAAGRIN2B
SCHEMBL29950951 0.79 ENPP2 (0.46) ENPP2ORAI1ORAI2ORAI3ALDH1A1
SCHEMBL29951001 0.79 GRIA1 (0.40) KCNK3KCNK9KDM4EGAAGRIN2B
SCHEMBL29951401 0.77 ENPP2 (0.53) ENPP2ORAI1ORAI2ORAI3KCNK3
SCHEMBL29956737 0.77 ENPP2 (0.48) ENPP2ORAI1ORAI2ORAI3KCNK3
Magnesium Chloride Anhydrous SCHEMBL20694977 0.77 ENPP2 (0.52) ENPP2ORAI1ORAI2ORAI3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-6645939-B1 Very late antigen-4 (VLA) integrin antagonists; antiallergens, antiasthmatics, and antiinflammatory agents; multiple sclerosis, autoimmune disease treatment MERCK & CO., INC. 2003-11-11 US disclosed